BBT-207

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameBBT-207
Drug Alias NameBBT-207
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR 19del inhibitorsEGFR C797S inhibitorsEGFR L858R inhibitors +[4] 
TargetsEpidermal growth factor receptor erbB1EGFR 19delEGFR C797S +[4] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBridge Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesBridge Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A